The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

Google and Perceptra, a Google technology licensing partner, are joining forces to provide AI-powered diabetic-retinopathy (DR) screening to around 1 million people in underserved communities across ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...